LP-1

Cell line name LP-1

Synonyms LP1

Accession CVCL_0012

Resource Identification Initiative To cite this cell line use: LP-1 (RRID:CVCL_0012)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Population: Caucasian.

Characteristics: Produces IgG lambda.

Doubling time: 50 hours (PubMed=2784066); 48 hours (PubMed=25984343); 35-80 hours (Note=Depending on cell density) (DSMZ=ACC-41).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: B-cell; CL=CL_0000236.

Sequence variations

Gene fusion; HGNC; 5477; IGH + HGNC; 12766; NSD2; Name(s)=IGH-NSD2, IGH-WHSC1 (PubMed=31160637).

Mutation; HGNC; 3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Unspecified (PubMed=11157491).

Mutation; HGNC; 12033; TRAF3; Simple; p.Lys286Ilefs*7 (c.857_870delAGAGCATACAAAGT); Zygosity=Homozygous (PubMed=17692805).

Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP=907791).

HLA typing Source: PubMed=25688540

Class I

HLA-A A*03,24

HLA-B B*07,18

HLA-C C*07

 

Source: PubMed=26589293

Class I

HLA-A A*26:01,30:01

HLA-B B*18:01,35:03

HLA-C C*04:01,07:01

Class II

HLA-DQ DQA1*03:02,05:01

DQB1*03:02,03:02

HLA-DR DRB1*04:03,11:04

 

Source: DSMZCellDive=ACC-41

Class I

HLA-A A*26:01:01,30:01:01

HLA-B B*18:01:01,35:03:01

HLA-C C*04:01:01;07:01:01

Class II

HLA-DP DPA1*01:03:01,01:03:01

DPB1*04:02:01,04:01:01

HLA-DQ DQA1*03:01:01,05:05:01

DQB1*03:01:01,03:02:01

HLA-DR DRA*01:01:01,01:01:01

DRB1*04:03:01,11:04:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0.21

Native American 0

East Asian, North 3.2

East Asian, South 0

South Asian 2.32

European, North 42.82

European, South 51.44

Disease Plasma cell myeloma (NCIt: C3242)

Multiple myeloma (ORDO: Orphanet_29073)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Female

Age at sampling 56Y

Category Cancer cell line

STR profile Source(s): Cosmic-CLP=907791; DSMZ=ACC-41; PubMed=25877200

 

Markers:

Amelogenin X

CSF1PO 11,12

D2S1338 18,26

D3S1358 16,18

D5S818 11

D7S820 11,12

D8S1179 13 (DSMZ=ACC-41)

13,15 (PubMed=25877200)

D13S317 12

D16S539 11,12

D18S51 18

D19S433 14

D21S11 30,31

FGA 20,21

Penta D 12

Penta E 10,11

TH01 7,8

TPOX 11

vWA 17

 

Publications

PubMed=2784066; DOI=10.1182/blood.V73.4.1020.1020

Pegoraro L., Malavasi F., Bellone G., Massaia M., Boccadoro M., Saglio G., Guerrasio A., Benetton G., Lombardi L., Coda R., Avanzi G.C.

The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.

Blood 73:1020-1027(1989)

 

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x

Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M.

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Br. J. Haematol. 107:392-395(1999)

 

DOI=10.1007/0-306-46877-8_4

Jernberg-Wiklund H., Nilsson K.

Multiple myeloma cell lines.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

 

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Leuk. Res. 24:681-703(2000)

 

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

 

PubMed=11157491; DOI=10.1182/blood.V97.3.729

Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Blood 97:729-736(2001)

 

PubMed=16956823

Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.

The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.

Haematologica 91:1234-1240(2006)

 

PubMed=17171682; DOI=10.1002/gcc.20404

Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Genes Chromosomes Cancer 46:226-238(2007)

 

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698

Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P.R., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Cancer Cell 12:131-144(2007)

 

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

Characterization of MYC translocations in multiple myeloma cell lines.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

 

PubMed=18700954; DOI=10.1186/1755-8794-1-37; PMCID=PMC2531129

Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Lambertenghi-Deliliers G., Neri A.

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

BMC Med. Genomics 1:37.1-37.9(2008)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235

Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Haematologica 96:574-582(2011)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)